CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
Rhea-AI Summary
CervoMed (NASDAQ: CRVO) will present Phase 2b RewinD-LB analyses at AD/PD 2026 in Copenhagen, March 17-21, 2026. Presentations include an oral talk on March 21 and a symposium on March 20.
New secondary analyses by pre-specified plasma pTau181 and PK/PD data further support the planned Phase 3 dosing regimen and the chosen patient-enrichment cutoff for DLB patients without Alzheimer’s co-pathology.
Positive
- Phase 2b RewinD-LB showed statistically significant slowing in selected DLB patients
- Pre-specified pTau181 analyses support enrichment cutoff for planned Phase 3
- PK/PD analyses bolster proposed neflamapimod dosing regimen
Negative
- Efficacy reported only in DLB patients without Alzheimer’s co-pathology
- Planned Phase 3 remains to be started; results are not yet confirmatory
- Enrichment by pTau181 may reduce eligible patient pool for Phase 3
Key Figures
Market Reality Check
Peers on Argus
CRVO is down 9.05% while tracked biotech peers show mixed moves (e.g., IMUX up 6.23%, ANEB down 20%). With only one peer in momentum scanners and no same-day peer news, trading appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Investor conferences | Positive | -0.3% | Announced participation in March 2026 healthcare investor conferences and meetings. |
| Mar 04 | Phase 3 prep | Positive | +0.3% | Reported Phase 1 results and selected 50 mg TID dosing for planned DLB Phase 3. |
| Feb 18 | ALS platform entry | Positive | +8.6% | Neflamapimod chosen for UK EXPERTS-ALS biomarker-driven ALS evaluation platform. |
| Dec 04 | DLB efficacy data | Positive | -4.1% | Late-breaking RewinD-LB data showed slowed DLB progression and biomarker improvements. |
| Dec 02 | Biomarker update | Positive | -10.8% | Presented DLB biomarker data showing GFAP reduction and Aβ42/40 ratio increase with treatment. |
Recent history shows mixed price reactions to largely positive clinical and conference news, with several DLB data updates drawing negative next-day moves.
Over the past months, CervoMed has steadily advanced neflamapimod in dementia with Lewy bodies (DLB) and broadened its footprint into ALS. Late 2025 CTAD presentations highlighted Phase 2b RewinD-LB efficacy and biomarker improvements but were followed by share declines. In February 2026, inclusion in the UK EXPERTS-ALS platform generated a stronger positive reaction. Early March 2026 updates on selecting a Phase 3 dosing regimen and investor conference participation drew only small moves. Today’s AD/PD 2026 presentation plans fit this ongoing DLB-focused clinical narrative.
Market Pulse Summary
This announcement highlights continued momentum for neflamapimod in dementia with Lewy bodies, with new Phase 2b analyses and PK/PD data guiding the planned Phase 3 design and dosing. The AD/PD 2026 presentations build on prior CTAD results from late 2025 and the company’s 2026 updates on formulation and regimen selection. Investors may focus on how these data refine patient selection, strengthen the DLB thesis, and position the program ahead of the planned pivotal trial.
Key Terms
dementia with lewy bodies medical
dlb medical
ptau181 medical
p38 map kinase medical
pk/pd medical
AI-generated analysis. Not financial advice.
Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB)
DLB is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments in the United States or European Union
BOSTON, March 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an oral, small molecule, drug candidate targeting critical disease processes underlying degenerative disorders of the brain, will be featured in an oral presentation and a scientific symposium at AD/PD 2026 in Copenhagen, Denmark, taking place March 17-21, 2026.
In the Phase 2b RewinD-LB trial, neflamapimod demonstrated a statistically significant and clinically meaningful slowing of clinical progression in patients with dementia with Lewy bodies (DLB) who did not have Alzheimer’s disease (AD) co-pathology during the trial’s extension phase. The secondary analyses of data from the trial to be presented at AD/PD 2026 will include new outcomes by pre-specified plasma pTau181 levels that further support the cutoff to be utilized in the Company’s planned Phase 3 trial in DLB patients to enrich for those without AD co-pathology.
The primary and secondary analyses of the study will be presented by Dr. John-Paul Taylor, MBBS(hons) MRCPsych PhD, Professor of Translational Dementia Research at Newcastle University, United Kingdom (UK) and Chief Investigator of the RewinD-LB trial for the UK.
In addition, CervoMed will be sponsoring a scientific symposium that focuses on how advances in DLB research are leading to new, mechanism-based drug development strategies. The symposium will include presentations from Dr. Niels Prins, MD, PhD, Brain Research Center, Amsterdam, and Dr. John Alam, CEO, CervoMed, and will highlight scientific, mechanistic, pharmacologic, and clinical data supporting the inhibition of p38 map kinase as a potential promising treatment for DLB. This will include results of new PK/PD analyses (i.e., blood drug concentration relationships) from the RewinD-LB trial that increase the understanding of neflamapimod dose-response in DLB and support the Company’s proposed dosing regimen for its planned Phase 3 trial.
Oral Presentation
Title: Neflamapimod Treatment Effects In Patients With Dementia With Lewy Bodies Without Concomitant Ad Pathology In The Rewind-LB Clinical Study (NCT05869669)
Session: ID 2617
Location: Auditorium 10
Authors: John-Paul Taylor, Stephen Gomperts, Lawrence Honig, Niels Prins, Amanda Gardner, Kelly Blackburn, John Alam, James Galvin
Date/Time: Saturday, March 21 at 14:25-14:40 CET
Scientific Symposium
Title: From Mechanisms to Medicines: Advancing Drug Development in Dementia With
Lewy Bodies
Location: Hall A1
Presenters: Niels Prins, MD, PhD, Brain Research Center, Amsterdam and John Alam, MD, CEO CervoMed
Date/Time: Friday, March 20, 2026 at 16:20 CET
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology. The Company plans to initiate a global, pivotal Phase 3 trial in patients with DLB, enriched for those without AD co-pathology, in the second half of 2026, subject to available funding.
Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: that neflamapimod will have any particular pharmacokinetic profile or achieve any specific plasma drug concentrations, including whether such profile or concentrations will replicate those observed in any prior clinical trial or nonclinical study; the therapeutic potential of neflamapimod in DLB or any other indication, including the degree of sustainability of any therapeutic effects; the anticipated timing and achievement of clinical and development milestones, including the Company’s initiation of the Company’s planned Phase 3 trial in DLB patients without AD co-pathology and the announcement of any data therefrom; any other expected or implied benefits or results, including the extent (if any) to which neflamapimod may demonstrate efficacy or other clinical or biomarker improvements in patients; and the Company’s need to acquire sufficient funding, including funding for its planned Phase 3 trial. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) on March 17, 2025, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.
Contacts
Media:
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431
Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902
FAQ
What will CervoMed (CRVO) present at AD/PD 2026 on March 21, 2026?
How do the pTau181 analyses affect CervoMed's planned Phase 3 trial (CRVO)?
What new PK/PD data will CervoMed (CRVO) discuss at the AD/PD 2026 symposium?
Who are the key presenters for CervoMed (CRVO) at AD/PD 2026 and when are they speaking?
What was the specific patient subgroup showing benefit in CervoMed's RewinD-LB trial (CRVO)?
